RESUMO
OBJECTIVE: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness. STUDY DESIGN: Prospective observational registry enrolling those who received >or=1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites. RESULT: Of 19 548 subjects enrolled, 40% were born before 32 weeks', 48% between 32 and 35 weeks' and 12% after 35 weeks' gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates. CONCLUSION: Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Antivirais/uso terapêutico , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Anticorpos Monoclonais Humanizados , Hospitalização , Humanos , Lactente , Recém-Nascido , Recém-Nascido Prematuro , Palivizumab , Estudos Prospectivos , Sistema de RegistrosRESUMO
Disseminated adenovirus infection with fatal hepatic necrosis has been reported in 16 patients, 15 of whom had immunocompromising conditions. Herein we report three patients with AIDS and fatally disseminated adenovirus infection with hepatic necrosis. The median age of these 16 patients was 4.7 years, and their illness was characterized by fever (13 of 16 patients), coagulopathy (10 of 16), lower respiratory tract disease (10 of 16), and gastrointestinal hemorrhage (five of 16) in addition to clinical evidence of hepatitis. The adenoviruses isolated were the commonly found serotypes 1, 2, 3, 5, and 7 for 13 of the 15 cases for which this determination was available. With the high frequency of adenovirus infection in humans and the increasing prevalence of human immunodeficiency virus infection in children, it seems likely that this syndrome will continue to be seen.
Assuntos
Infecções por Adenoviridae/complicações , Infecções por HIV/complicações , Síndromes de Imunodeficiência/complicações , Hepatopatias/etiologia , Infecções por Adenoviridae/patologia , Adulto , Criança , Feminino , Humanos , Tolerância Imunológica , Lactente , Fígado/patologia , Hepatopatias/patologia , Masculino , NecroseRESUMO
To our knowledge, median cleft of nose without apparent hypertelorism (bifid nose) has been reported only twice [Esser, 1939; Boo-chai, 1965]. We report five individuals in 3 generations of a family who had a bifid nose without apparent hypertelorism or mental retardation. In this family bifid nose was most likely an autosomal dominant trait.
